CLYMClimb Bio Inc

Healthcare
$10.86+558% 1Y

The financials

Climb Bio Inc by the numbers

The next results filing is expected around Nov 5, 2026, the same week as a year ago.

Climb Bio Inc income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$15M−$11Mn/a
Net income−$13M−$8.7Mn/a
Diluted EPS−$0.18−$0.13n/a

Biotechnology

Ranks #179 of 196 by RyuScore

Compare peers
PRME-8.2%
Prime Medicine, Inc.
ZVRA-0.72%
ZEVRA THERAPEUTICS, INC.
ANNX-0.99%
Annexon, Inc.
GYRE-3.8%
GYRE THERAPEUTICS, INC.
IMMX-1.9%
Immix Biopharma, Inc.
FDMT+0.79%
4D Molecular Therapeutics, Inc.